Myocardial phosphodiesterases and regulation of cardiac contractility in health and cardiac disease

Cardiovascular Drugs and Therapy

Volumn 21, Issue 3, 2007, Pages 171-194

  Osadchii, Oleg E ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

cAMP; Compartmentalized signalling; Heart failure; Myocardial contractility; Phosphodiesterase

Indexed keywords

1,3 DIHYDRO 1,3,3 TRIMETHYL 5 (1,4,5,6 TETRAHYDRO 4 METHYL 6 OXO 3 PYRIDAZINYL) 2H INDOL 2 ONE; 4 (3 BUTOXY 4 METHOXYBENZYL) 2 IMIDAZOLIDINONE; 5 (4 ACETAMIDOPHENYL) 2(1H) PYRAZINONE; 8 BROMO CYCLIC AMP; 9 (2 HYDROXY 3 NONYL)ADENINE; AMRINONE; BUCLADESINE; CAFFEINE; CILOSTAZOL; CYCLIC AMP; ENOXIMONE; FORSKOLIN; IMAZODAN; INDOLIDAN; ISOBUTYLMETHYLXANTHINE; ISOPRENALINE; LEVOSIMENDAN; METOPROLOL; MILRINONE; O NORPIMOBENDAN; PAPAVERINE; PENTOXIFYLLINE; PHOSPHODIESTERASE INHIBITOR; PIMOBENDAN; PIROXIMONE; ROLIPRAM; SILDENAFIL; SULMAZOLE; THEOPHYLLINE; UNINDEXED DRUG;

BINDING AFFINITY; BINDING SITE; CALCIUM CELL LEVEL; CALCIUM SIGNALING; CALCIUM TRANSPORT; CELLULAR DISTRIBUTION; DOWN REGULATION; DRUG EFFECT; DRUG RESPONSE; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME KINETICS; HEART DISEASE; HEART FAILURE; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HEART MUSCLE ISCHEMIA; HEART VENTRICLE HYPERTROPHY; HUMAN; MYOFILAMENT; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PULMONARY HYPERTENSION; RECEPTOR BLOCKING; REVIEW; SARCOPLASMIC RETICULUM; SODIUM CALCIUM EXCHANGE;

ANIMALS; CYCLIC AMP; HEART DISEASES; HUMANS; ISOENZYMES; KINETICS; MYOCARDIAL CONTRACTION; MYOCARDIUM; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES;

EID: 34249324524     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10557-007-6014-6     Document Type: Review

References (247)

1. Anderson JL. Hemodynamic and clinical benefits with intravenous milrinone in severe chronic heart failure: results of a multicenter study in the United States. Am Heart J 1991;121:1956-64.
2. Klocke RK, Mager G, Kux A, Hopp HW, Hilger HH. Effects of a twenty-four-hour milrinone infusion in patients with severe heart failure and cardiogenic shock as a function of the hemodynamic initial condition. Am Heart J 1991;121:1965-73.
3. Konstam MA, Cody RJ. Short-term use of intravenous milrinone for heart failure. Am J Cardiol 1995;75:822-6.
4. Loh E, Elkayam U, Cody R, Bristow M, Jaski B, Colucci WS. A randomized multicenter study comparing the efficacy and safety of intravenous nitroglycerin in patients with advanced heart failure. J Card Fail 2001;7:114-21.
5. Feldman AM, Bristow MR, Parmley WW, Carson PE, Pepine CJ, Gilbert EM, et al. Effects of vesnarinone on morbidity and mortality in patients with heart failure. Vesnarinone Study Group. N Engl J Med 1993;329:149-55.
6. Nony P, Boissel JP, Lievre M, Leizorovicz A, Haigh MC, Fareh, et al. Evaluation of the effect of phosphodiesterase inhibitors on mortality in chronic heart failure patients. A meta-analysis. Eur J Clin Pharmacol 1994;46:191-6.
7. Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBlanco R, Zeldis SM, et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med 1991;35:1468-75.
8. Uretsky BF, Jessup M, Konstam MA, Dec GW, Leier CV, Benotti J, et al. Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure. Lack of benefit compared with placebo. Enoximone Multicenter Trial Group. Circulation 1990;82:774-80
9. Colucci WS, Wright RF, Jaski BE, Fifer MA, Braunwald E. Milrinone and dobutamine in severe heart failure: differing hemodynamic effects and individual patient responsiveness. Circulation 1986;73:III-175-83.
10. Grose R, Strain J, Greenberg M, Le Jemtel TH. Systemic and coronary effects of intravenous milrinone and dobutamine in congestive heart failure. J Am Coll Cardiol 1986;7:1107-1113.
11. Karlsberg RP, De Wood MA, De Maria AN, Berk MR, Lasher KP. Comparative efficacy of short-term intravenous infusions of milrinone and dobutamine in acute congestive heart failure following acute myocardial infarction. Milrinone-Dobutamine Study Group. Clin Cardiol 1996;19:21-30.
12. Kawamura A, Yoshikawa T, Takahashi T, Hayashi T, Takahashi E, Anzai T, et al. Randomized trial of phosphodiesterase inhibitors versus catecholamines in patients with acutely decompensated heart failure. Jpn Circ J 2001;65:858-62.
13. Kieback AG, Iven H, Stolzenburg K, Baumann G. Saterinone, dobutamine, and sodium nitroprusside: comparison of cardiovascular profiles in patients with congestive heart failure. J Cardiovasc Pharmacol 1998;32:629-36.
14. Lowes BD, Tsvetkova T, Eichhorn EJ, Gilbert EM, Bristow MR. Milrinone versus dobutamine in heart failure subjects treated chronically with carvedilol. Int J Cardiol 2001;81:141-9.
15. Mager G, Klocke R, Kux A, Hopp HW, Hilger HH. Phosphodiesterase III inhibition or adrenoreceptor stimulation: milrinone as an alternative to dobutamine in the treatment of severe heart failure. Am Heart J 1991;121:1974-83.
16. Monrad ES, Baim DS, Smith HS, Lanone AS. Milrinone, dobutamine, and nitroprusside: comparative effects on hemodynamics and myocardial energetics in patients with severe congestive heart failure. Circulation 1986;73:III-168-74.
17. Cusick DA, Pfeifer PB, Quigg RJ. Effects of intravenous milrinone followed by titration of high-dose oral vasodilator therapy on clinical outcome and rehospitalization rates in patients with severe heart failure. Am J Cardiol 1998;82:1060-5.
18. Milfred-LaForest SK, Shubert J, Mendoza B, Flores I, Eisen HJ, Pina IL. Tolerability of extended duration intravenous milrinone in patients hospitalized for afvanced heart failure and the usefulness of uptitration of oral angiotensin-converting enzyme inhibitors. Am J Cardiol 1999;84:894-9.
19. Bader FM, MacGregor JF, Gilbert EM. Initiation and use of beta-blockers in class IV heart failure. Curr Heart Fail Rep 2004;1:72-6.
20. Bristow MR. Beta-adrenergic receptor blockade in chronic heart failure. Circulation 2000;101:558-69.
21. Hauptman PJ, Woods D, Prirzker MR. Novel use of a short-acting intravenous beta blocker in combination with inotropic therapy as a bridge to chronic oral beta blockade in patients with advanced heart failure. Clin Cardiol 2002;25:247-9.
22. Kumar A, Choudhary G, Antonio C, Just V, Jain A, Henney L, et al. Carvedilol titration in patients with congestive heart failure receiving inotropic therapy. Am Heart J 2001;142:512-5.
23. Aranda JM, Schofield RS, Pauly DF, Cleeton TS, Walker TC, Monroe VS, Jr, et al. Comparison of dobutamine versus milrinone therapy in hospitalized patients awaiting cardiac transplantation: a prospective, randomized trial. Am Heart J 2003;145:324-9.
24. Shakar SF, Abraham WT, Gilbert EM, Robertson A. Combined oral positive inotropic and beta- blocker therapy for treatment of refractory class IV heart failure. J Am Coll Cardiol 1998;31:1336-40.
25. Shakar SF, Bristow MR. Low-level inotropic stimulation with type III phosphodiesterase inhibitors in patients with advanced symptomatic chronic heart failure receiving beta- blocking agents. Curr Cardiol Rep 2001;3:224-31.
26. Beavo JA. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev 1995;75:725-48.
27. Conti M, Nemoz G, Sette C, Vicini E. Recent progress in understanding the hormonal regulation of phosphodiesterases. Endocr Rev 1995;16:370-89.
28. Manganiello VC, Murata T, Taira M, Belfrage P, Degerman E. Diversity in cyclic nucleotide phosphodiesterase isoenzyme families. Arch Biochem Biophys 1995;322:1-13.
29. Ahluwalia G, Rhoads AR, Lulla M. Particulate cyclic 3,'5'-nucleotide phosphodiesterase and calmodulin of cardiac muscle. Int J Biochem 1984;16:483-8.
30. Kithas PA, Artman M, Thompson WJ, Strada SJ. Subcellular distribution of high-affinity type IV cyclic AMP phosphodiesterase activity in rabbit ventricular myocardium: relations to the effects of cardiotonic drugs. Circ Res 1988;62:782-9.
31. Masuoka H, Ito M, Nakano T, Naka M, Tanaka T. Effects of amrinone and enoximone on the subclasses of cyclic AMP phosphodiesterase from human heart and kidney. J Cardiovasc Pharmacol 1990;15:302-7.
32. m, cGMP-inhibited camp phosphodiesterase in mammalian myocardium. Biochem Biophys Res Commun 1993;190:516-21.
33. Weishaar RE, Kobylarz-Singer DC, Steffen RP, Kaplan HR. Subclasses of cyclic AMP-specific phosphodiesterase in left ventricular muscle and their involvement in regulating myocardial contractility. Circ Res 1987;61:539-47.
34. Lugnier C, Keravis T, Le Bec A, Pauvert O, Proteau S, Rousseau E. Characterization of cyclic nucleotide phosphodiesterase isoforms associated to isolated cardiac nuclei. Biochim Biophys Acta 1999;1472:431-46.
35. Sugioka M, Ito M, Masuoka H, Ichikawa K, Konishi T, Tanaka T, et al. Identification and characterization of isoenzymes of cyclic nucleotide phosphodiesterase in human kidney and heart, and the effects of new cardiotonic agents on these isoenzymes. Naunyn-Schmiedeberg's Arch Pharmacol 1994;350:284-93.
36. Chiu WC, Kedem J, Weiss HR, Tse J, Cheinberg BV, Scholz PM. Milrinone, a cyclic AMP-phosphodiesterase inhibitor, has differential effects on regional myocardial work and oxygen consumption in experimental left ventricular hypertrophy. Cardiovasc Res 1994;28:1360-5.
37. Smith CJ, Huang R, Sun D, Ricketts S, Hoegler C, Ding J-Z, et al. Development of decompensated dilated cardiomyopathy is associated with decreased gene expression and activity of the milrinone-sensitive cAMP phosphodiesterase PDE 3A. Circulation 1997;96:3116-23.
38. Prigent A, Nemoz G, Yachaoui Y, Pageaux JF, Pacheco H. Cyclic nucleotide phosphodiesterase from a particulate fraction of rat heart. Solubilization and characterization of a single enzymatic form. Biochem Biophys Res Commun 1981;102:355-64.
39. Thompson WJ, Appleman MM. Characterization of cyclic nucleotide phosphodiesterases of rat tissues. J Biol Chem 1971;246:3145-50.
40. Louis PJS, Sulakhe PV. Adenylate cyclase, guanylate cyclase and cyclic nucleotide phosphodiesterases of guinea-pig cardiac sarcolemma. Biochem J 1976;158:535-41.
41. Muller B, Stoclet JC, Lugnier C. Cytosolic and membrane-bound cyclic nucleotide phosphodiesterases from guinea-pig cardiac ventricles. Eur J Pharmacol 1992;225:263-72.
42. Lugnier C, Muller B, Le Bec A, Beaudry C, Rousseau E. Characterization of indolidan- and rolipram-sensitive cyclic nucleotide phosphodiesterases in canine and human cardiac microsomal fractions. J Pharmacol Exp Ther 1993;265:1142-51.
43. Okruhlicova L, Tribulova N, Eckly A, Lugnier C, Slezak J. Cytochemical distribution of cyclic AMP-dependent 3′,5′-nucleotide phosphodiesterase in the rat myocardium. Histochem J 1996;28:165-72.
44. Shahid M, Nicholson CD. Comparison of cyclic nucleotide phosphodiesterase isoenzymes in rat and rabbit ventricular myocardium: positive inotropic and phosphodiesterase inhibitory effects of Org 30029, milrinone and rolipram. Naunyn-Schmiedeberg's Arch Pharmacol 1990;342:698-705.
45. m, cGMP-inhibited cAMP phosphodiesterase in cardiac and skeletal muscle. Biochem Biophys Res Commun 1996;225:1058-62.
46. Harrison SA, Reifsnyder DH, Gallis B, Cadd GG, Beavo JA. Isolation and characterization of bovine cardiac muscle cGMP-inhibited phosphodiesterase: a receptor for new cardiotonic drugs. Mol Pharmacol 1986;29:506-14.
47. Shahid M, Wilson M, Nicholson CD, Marshall RJ. Species-dependent differences in the properties of particulate cyclic nucleotide phosphodiesterase from rat and rabbit ventricular myocardium. J Pharm Pharmacol 1990;42:283-4.
48. Lugnier C, Gauthier C, Le Bec A, Soustre H. Cyclic nucleotide phosphodiesterases from frog atrial fibers: isolation and drug sensitivities. Am J Physiol 1992;262:H654-60.
49. Kithas PA, Artman M, Thompson WJ, Strada SJ. Subcellular distribution of high-affinity type IV cyclic AMP phosphodiesterase activities in rabbit ventricular myocardium: relations to postnatal maturation. J Mol Cell Cardiol 1989;21:507-17.
50. Beltman J, Sonnenburg WK, Beavo JA. The role of protein phosphorylation in the regulation of cyclic nucleotide phosphodiesterases. Mol Cell Biochem 1993;127/128:239-53.
51. Manganiello VC, Taira M, Degerman E, Belfrage P. Type III cGMP-inhibited cyclic nucleotide phosphodiesterases. Cell Signal 1995;7:445-55.
52. Sette C, Conti M. Phosphorylation and activation of a cAMP-specific phosphodiesterase by the cAMP-dependent protein kinase. J Biol Chem 1996;271:16526-34.
53. Wechsler J, Choi YH, Krall J, Ahmad F, Manganiello VC, Movsesian MA. Isoforms of cyclic nucleotide phosphodiesterase PDE3A in cardiac myocytes. J Biol Chem 2002;277:38072-8.
54. Rochais F, Vandecasteele G, Lefebvre F, Lugnier C, Lum C, Mazel J-L, et al. Negative feedback exerted by cAMP- dependent protein kinase and cAMP phosphodiesterase on subsarcolemmal cAMP signals in intact cardiac myocytes. J Biol Chem 2004;279:52095-105.
55. Bethke T, Klimkiewicz A, Kohl C, von der Leyen H, Mehl H, Mende U, et al. Effects of isomazole on force of contraction and phosphodiesterase isoenzymes I-IV in nonfailing and failing human hearts. J Cardiovasc Pharmacol 1991;18:386-97.
56. Reeves ML, Leigh BK, England PJ. The identification of a new cyclic nucleotide phosphodiesterase activity in human and guinea-pig cardiac ventricle. Biochem J 1987;241:535-41.
57. Von der Leyen H, Mende U, Meyer W, et al. Mechanism underlying the reduced positive inotropic effects of the phosphodiesterase III inhibitors pimobendan, adibendan and saterinone in failing as compared to nonfailing human cardiac muscle preparations. Naunyn-Schmiedeberg's Arch Pharmacol 1991;344:90-100.
58. Zimmermann W, Scholz H, Schumacher C, Wenzlaff H, Haverich A. Effects of saterinone and its enantiomers R(+)-saterinone and S(-)-saterinone on the phosphodiesterase isoenzymes from ventricular tissue of failing human hearts and porcine hearts. Naunyn-Schmiedeberg's Arch Pharmacol 1994;349:611-8.
59. Bethke T, Meyer W, Schmitz W, Scholz H, Stein B, Thomas K, et al. Phosphodiesterase inhibition in ventricular cardiomyocytes from guinea-pig hearts. Br J Pharmacol 1992;107:127-33.
60. Bode DC, Kanter JR, Brunton LL. Cellular distribution of phosphodiesterase isoforms in rat cardiac tissue. Circ Res 1991;68:1070-9.
61. Harrison SA, Chang ML, Beavo JA. Differential inhibition of cardiac cyclic nucleotide phosphodiesterase isozymes by cardiotonic drugs. Circulation 1986;73:III-109-16.
62. Hansen RS, Beavo JA. Purification of two calcium/calmodulin-dependent forms of cyclic nucleotide phosphodiesterase by using conformation-specific monoclonal antibody chromatpgraphy. Proc Natl Acad Sci U S A 1982;79:2788-92.
63. Wallis RM, Corbin JD, Francis SH, Ellis P. Tissue distribution of phosphodiesterase families and the effects of sildenafil om tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro. Am J Cardiol 1999;83:3C-12C.
64. Kostic MM, Erdogan S, Rena G, Borchert G, Hoch B, Bartel S, et al. Altered expression of PDE1 and PDE4 cyclic nucleotide phosphodiesterase isoforms in 7-oxo-prostacyclin-preconditioned rat heart. J Mol Cell Cardiol 1997;29:3135-46.
65. Brunkhorst D, Leyen H, Meyer W, Nigbur R, Schmidt-Schumacher C, Scholz H. Relation of positive inotropic and chronotropic effects of pimobendan, UD-CG 212 CL, milrinone and other phosphodiesterase inhibitors to phosphodiesterase III inhibition in guinea-pig heart. Naunyn-Schmiedeberg's Arch Pharmacol 1989;339:575-83.
66. Yu H, Cai JJ, Lee HC. Cyclic AMP-dependent phosphodiesterase isozyme-specific potentiation by protein kinase C in hypertrophic cardiomyopathic hamster hearts. Mol Pharmacol 1996;50:549-55.
67. Sharma RK. Phosphorylation and characterization of bovine heart calmodulin-dependent phosphodiesterase. Biochemistry 1991;30:5963-8.
68. Lee HC, Cai JJ, Yu H. Effect of protein kinase C on cyclic 3′, 5′-adenosine monophosphate-dependent phosphodiesterase in hypertrophic cardiomyopathic hamster hearts. J Pharmacol Exp Ther 1994;270:1171-6.
69. Martins TJ, Mumby MC, Beavo JA. Purification and characterization of a cyclic GMP-stimulated cyclic nucleotide phosphodiesterase from bovine tissues. J Biol Chem 1982;257:1973-9.
70. Ito M, Tanaka T, Saitoh M, Masuoka H, Nakano T, Hidaka H. Selective inhibition of cyclic AMP phosphodiesterase from various human tissues by milrinone, a potent cardiac bipyridine. Biochem Pharmacol 1988;37:2041-4.
71. Simmons MA, Hartzell HC. Role of phosphodiesterase in regulation of calcium current in isolated cardiac myocytes. Mol Pharmacol 1988;33:664-71.
72. Reeves ML, England PJ, Murray KJ. Compartments of cyclic-AMP-dependent protein kinase in perfused guinea-pig hearts. Biochem Soc Trans 1987;15:955-56.
73. Mery PF, Pavoine C, Pecker F, Fischmeister R. Erythro-9-(2-hydroxy-3- nonyl) adenine inhibits cGMP-stimulated phosphodiesterase in isolated cardiac myocytes. Mol Pharmacol 1995;48:121-30.
74. Podzuweit T, Nennstiel P, Muller A. Isozyme selective inhibition of cGMP-stimulated cyclic nucleotide phosphodiesterases by erythro-9-(2-hydroxy-3- nonyl) adenine. Cell Signal 1995;7:733-8.
75. Mongillo M, Tocchetti CG, Terrin A, Lissandron V, Cheung Y-F, Dostmann WR, et al. Compartmentalized phosphodiesterase-2 activity blunts β-adrenergic cardiac inotropy via an NO/cGMP-dependent pathway. Circ Res 2006;98:226-34.
76. Silver PJ, Harris AL, Canniff PC, Lepore RE, Bentley RG, Hamel LT, et al. Phosphodiesterase isozyme inhibition, activation of the cAMP system, and positive inotropy mediated by milrinone in isolated guinea pig cardiac muscle. J Cardiovasc Pharmacol 1989;13:530-40.
77. 2+ current by activation of adenylyl cyclase and inhibition of phosphodiesterase. Nature 1990;345:158-61.
78. s-coupled receptors in adult rat ventricular myocytes. Circ Res 2006;98:1081-8.
79. Ding B, Abe J, Wei H, Huang Q, Walsh RA, Molina CA, et al. Functional role of phosphodiesterase 3 in cardiomyocyte apoptosis. Circulation 2005;111:2469-76.
80. Hambleton R, Krall J, Tikishvili E, Honnegar M, Ahmad F, Manganiello VC, et al. Isoforms of cyclic nucleotide phosphodiesterase PDE3 and their contribution to cAMP hydrolytic activity in subcellular fractions of human myocardium. J Biol Chem 2005;280:39168-74.
81. Patrucco E, Notte A, Barberis L, Selvetella G, Maffei A, Brancaccio M, et al. PI3Kγ modulates the cardiac response to chronic pressure overload by distinct kinase-dependent and -independent effects. Cell 2004;118:375-87.
82. Kaasik A, Ohisalo JJ. Membrane-bound phosphodiesterases in rat myocardium. J Pharm Pharmacol 1996;48:962-4.
83. Shakur Y, Fong M, Hensley J, Cone J, Movsesian MA, Kambayashi J-I, et al. Comparison of the effects of cilostazol and milrinone on cAMP-PDE activity, intracellular cAMP and calcium in the heart. Cardiovasc Drugs Ther 2002;16:417-27.
84. Mongillo M, McSorley T, Evellin S, Sood A, Lissandron V, Terrin A, et al. Fluorescence resonance energy transfer-based analysis of cAMP dynamics in live neonatal rat cardiac myocytes reveals distinct functions of compartmentalized phosphodiesterases. Circ Res 2004;95:67-75.
85. Kauffman RF, Crowe VG, Utterback BG, Robertson DW. LY195115: a potent, selective inhibitor of cyclic nucleotide phosphodiesterase located in the sarcoplasmic reticulum. Mol Pharmacol 1986;30:609-616.
86. 3H]LY186126 in ventricular myocardium. Mol Pharmacol 1989;36:302-11.
87. 3H]LY186126, a cardiotonic phosphodiesterase inhibitor, in canine cardiac membranes. Circ Res 1989;65:154-163.
88. Movsesian MA, Smith CJ, Krall J, Bristow MR, Manganiello VC. Sarcoplasmic reticulum-associated cyclic adenosine 5'-monophosphate phosphodiesterase activity in normal and failing human hearts. J Clin Invest 1991;88:15-9.
89. Fougier S, Nemoz G, Prigent AF, et al. Purification of cAMP-specific phosphodiesterase from rat heart by affinity chromatography on immobilized rolipram. Biochem Biophys Res Commun 1986;138:205-14.
90. Richter W, Jin SLC, Conti M. Splice variants of the cyclic nucleotide phosphodiesterase PDE4D are differentially expressed and regulated in rat tissue. Biochem J 2005;388:803-11.
91. Lehnart SE, Wehrens XHT, Reiken S, Warrier S, Belevych AE, Harvey RD, et al. Phosphodiesterase 4D deficiency in the ryanodine-receptor complex promotes heart failure and arrhythmias. Cell 2005;23:25-35.
92. 2-adrenoceptor subtype-specific signaling in cardiac myocytes. Proc Natl Acad Sci U S A 2005;102:909-14.
93. Georget M, Mateo P, Vandecasteele G, Lipskaia L, Defer N, Hanoune J, et al. Cyclic AMP compartmentation due to increased cAMP-phosphodiesterase activity in transgenic mice with a cardiac-directed expression of the human adenylyl cyclase type 8. FASEB J 2003;17:1380-91.
94. Carlisle Michel JJ, Dodge KL, Wong W, Mayer NC, Langeberg LK, Scott JD. PKA-phosphorylation of PDE4D3 facilitates recruitment of the mAKAP signaling complex. Biochem J 2004;381:587-92.
95. Kajimoto K, Hagiwara N, Kasanuki H, Hosoda S. Contribution of phosphodiesterase isozymes to the regulation of L-type calcium current in human cardiac myocytes. Br J Pharmacol 1997;121: 1549-56.
96. 2+ current and developed tension in guinea-pig ventricular myocytes and papillary muscle: comparison with IBMX, milrinone and cilostazol. Cardiovasc Drugs Ther 1999;13:105-13.
97. Malecot CO, Arlock P, Katzung BG. Amrinone effects on electromechanical coupling and depolarization-induced automaticity in ventricular muscle of guinea-pigs and ferrets. J Pharmacol Exp Ther 1985;232:10-9.
98. Malecot CO, Bers DM, Katzung BG. Biphasic contractions induced by milrinone at low temperature in ferret ventricular muscle: role of the sarcoplasmic reticulum and transmembrane calcium influx. Circ Res 1986;59:151-62.
99. Sutko JL, Kenyon JL, Reeves JP. Effects of amrinone and milrinone on calcium influx into the myocardium. Circulation 1986;73:III-52-8.
100. Olson EM, Kim D, Smith TW, Marsh JD. Mechanism of the positive inotropic effect of milrinone in cultured embryonic chick ventricular cells. J Mol Cell Cardiol 1987;19:95-104.
101. Endoh M, Yanagisawa T, Taira N, Blinks JR. Effects of new inotropic agents on cyclic nucleotide metabolism and calcium transients in canine ventricular muscle. Circulation 1986;73:III-117-33.
102. Gwathmey JK, Morgan JP. The effects of milrinone and piroximone on intracellular calcium handling in working myocardium from the ferret. Br J Pharmacol 1985;85:97-108.
103. Miao L, Perreault CL, Travers KE, Morgan JP. Mechanisms of positive inotropic action of flosequinan, hydralazine, and milrinone on mammalian myocardium. Eur J Pharmacol 1997;321:201-8.
104. Morgan JP, Gwathmey JK, DeFeo T, Morgan KG. The effects of amrinone and related drugs on intracellular calcium in isolated mammalian cardiac and vascular smooth muscle. Circulation 1986;73:III-65-77.
105. Alousi AA, Johnson DC. Pharmacology of the bipyridines: amrinione and milrinone. Circulation 1986;73:III-10-24.
106. Onuaguluchi G, Tanz RD. Cardiac effects of amrinone on rabbit papillary muscle and guinea-pig Langendorff heart preparations. J Cardiovasc Pharmacol 1981;3:1342-55.
107. 2+ and related ions on the cardiac action of milrinone. J Cardiovasc Pharmacol 1988;11:591-600.
108. 2+ activation and the inotropic effect of pimobendan: comparison with milrinone. Circ Res 1988;63:911-22.
109. Levi RC, Alloatti G, Fischmeister R. Cyclic GMP regulates the Ca-channel current in guinea-pig ventricular myocytes. Pflugers Arch 1989;413:685-7.
110. Li Q, Himmel M, Ravens U. Effects of the new phosphodiesterase-III inhibitor R80122 on contractility and calcium current in human cardiac tissue. J Cardiovasc Pharmacol 1994;24:133-43.
111. Shirayama T, Pappano AJ. Biphasic effects of intrapipette cyclic guanosine monophosphate on L-type calcium current and contraction of guinea-pig ventricular myocytes. J Pharmacol Exp Ther 1996;279:1274-81.
112. Xiong W, Moore HM, Howlett SE, Ferrier GR. In contrast to forskolin and 3-isobutyl- 1-methylxanthine, amrinone stimulates the cardiac voltage-sensitive release mechanism without increasing calcium-induced calcium release. J Pharmacol Exp Ther 2001;298:954-63.
113. 2+ current in rat ventricular myocytes. Br J Pharmacol 1999;127:65-74.
114. Akita T, Joyner RW, Lu C, Kumar R, Hartzell C. Developmental changes in modulation of calcium currents of rabbit ventricular cells by phosphodiesterase inhibitors. Circulation 1994;90:469-78.
115. m cyclic AMP phosphodiesterases in cardiac cells. Mol Pharmacol 1990;38:426-433.
116. L in frog ventricular myocytes. J Physiol 2003;551:239-52.
117. Kirstein M, Rivet-Bastide M, Hatem S, Benardeu A, Mercadier JJ, Fischmeister R. Nitric oxide regulates the calcium current in isolated human atrial myocytes. J Clin Invest 1995;95:794-802.
118. Rivet-Bastide M, Vandecasteele G, Hatem S, Verde I, Bénardeau A, Mercadier J-J, et al. cGMP-stimulated cyclic nucleotide phosphodiesterase regulates the basal calcium current in human atrial myocytes. J Clin Invest 1997;99:2710-8.
119. 2+ release. J Pharmacol Exp Ther 2004;310:761-73.
120. 2+ current in guinea-pig ventricular cells. J Physiol 1991;443:387-404.
121. Mubagwa K, Shirayama T, Moreau M, Pappano AJ. Effects of PDE inhibitors and carbachol on the L-type Ca current in guinea pig ventricular myocytes. Am J Physiol 1993;265:H1353-63.
122. 2+ current regulation in cardiac cells. Life Sci 1991;48:2365-76.
123. 2+ channel activity by human natriuretic peptide in rabbit heart cells. Br J Pharmacol 1995;114:1076-82.
124. i in guinea-pig isolated ventricular myocytes. Eur J Pharmacol 1997;339:97-100.
125. Holmberg SRM, Williams AJ. Phosphodiesterase inhibitors and the cardiac sarcoplasmic reticulum calcium release channel: differential effects of milrinone and enoximone. Cardiovasc Res 1991;25:537-45.
126. 2+- release channel by analogues of sulmazole. Br J Pharmacol 1994;111:1212-20.
127. 2+-ATPase activity and share structural homologies. Proc Natl Acad Sci U S A 1985;82:7974-8.
128. Endoh M. Mechanisms of action of novel cardiotonic agents. J Cardiovasc Pharmacol 2002;40:323-38.
129. Van Meel JCA, Zimmermann R, Diederen W, Erdman E, Mrwa U. Increase in calcium sensitivity of cardiac myofibrils contributes to the cardiotonic action of sulmazole. Biochem Pharmacol 1988;37:213-220.
130. Wendt IR, Stephenson DG. Effects of caffeine on Ca-activated force production in skinned cardiac and skeletal muscle fibres of the rat. Pflugers Arch 1983;398:210-6.
131. 2+ uptake function of cardiac sarcoplasmic reticulum. Am J Physiol 2000;279:H1898-905.
132. Edes I, Kiss E, Kitada Y, Powers FM, Papp JG, Kramias EG, et al. Effects of levosimendan, a cardiotonic agent targeted to troponin C, on cardiac function and on phosphorylation and Ca2+ sensitivity of cardiac myofibrils and sarcoplasmic reticulum in guinea pig heart. Circ Res 1995;77:107-13.
133. Hain J, Onoue H, Mayrleitner M, Fleischer S, Schindler H. Phosphorylation modulates the function of the calcium release channel of sarcoplasmic reticulum from cardiac muscle. J Biol Chem 1995;270:2074-81.
134. 2+ and phosphorylation. Science 1995;267:1997-2000.
135. 2+ exchange by the β-adrenergic/protein kinase A pathway in guinea-pig ventricular myocytes at 37°C. Pflugers Arch 2000;439:822-8.
136. + ATPase in response to β-adrenergic hormone. Am J Physiol 1997;273:C893-901.
137. Gao J, Cohen IS, Mathias RT, Baldo GJ. The inhibitory effect of β-stimulation on the Na/K current in guinea-pig ventricular myocytes is mediated by a cAMP-dependent PKA pathway. Pflugers Arch 1998;435:479-84.
138. 2+] on the responses to milrinone in rat cardiac preparations. Eur J Pharmacol 1986;120:267-74.
139. ++ as an inotropic mechanism. Circulation 1986;73:III-85-98.
140. ++-sensitivity of myofibrillar Mg-adenosine triphosphatase isolated from normal human and canine hearts. J Pharmacol Exp Ther 1988;246:30-7.
141. Sata M, Sugiura S, Yamashita H, Aoyagi T, Momomura S, Serizawa T. Pimobendan directly sensitizes reconstituted thin filament to slide on cardiac myosin. Eur J Pharmacol 1995;290:55-9.
142. 2+ sensitivity of reconstituted thin filament. A study using a novel in vitro motility assay technique. Circ Res 1995;76:626-33.
143. Haikala H, Levijoki J, Linden IB. Troponin C-mediated calcium sensitization by levosimendan accelerates the proportional development of isometric tension. J Mol Cell Cardiol 1995;27:2155-65.
144. 2+ sensitizers EMD 57033 and CGP 48506 on cross-bridge cycling in human myocardium. J Pharmacol Exp Ther 2000;295:1284-90.
145. Choi OH, Shamim MT, Padgett WL, Daly JW. Caffeine and theophylline analogues: correlation of behavioral effects with activity as adenosine receptor antagonists and as phosphodiesterase inhibitors. Life Sci 1988;43:387-98.
146. Ukena D, Schudt C, Sybrecht JW. Adenosine receptor blocking xanthines as inhibitors of PDE isozymes. Biochem Pharmacol 1993;45:847-851.
147. i. Mol Pharmacol 1988;33:441-8.
148. Dorigo P, Gaion RM, Belluco P, Mosti L, Borea PA, Maragno I. An analysis of the mechanism of the inotropic action of some milrinone analogues in guinea-pig isolated atria. Br J Pharmacol 1991;104:867-72.
149. Floreani M, Fossa P, Gessi S, Mosti L, Borea PA, Dorigo P. New milrinone analogues: in vitro study of structure-activity relationships for positive inotropic effect, antagonism towards endogenous adenosine, and inhibition of cardiac type III phosphodiesterase. Naunyn-Schmiedeberg's Arch Pharmacol 2003;367:109-18.
150. i. Mol Pharmacol 1988;34:37-41.
151. Dorigo P, Maragno I. Interaction of amrinone with endogenous adenosine in guinea-pig atria. Br J Pharmacol 1986;87:623-9.
152. Dorigo P, Gaion RM, Maragno I. Involvement of purine compounds in the
153. Dorigo P, Gaion RM, Belluco P, Borea PA, Guerra L, Mosti L, et al. Antagonism towards endogenous adenosine and inhibition of cGI-PDE in the cardiac effects of amrinone, milrinone and related analogues. Gen Pharmacol 1992;23:535-541.
154. Earl CQ, Linden J, Weglicki WB. Biochemical mechanisms for the inotropic effect of the cardiotonic drug milrinone. J Cardiovasc Pharmacol 1986;8:864-72.
155. Alousi AA, Canter JM, Montenaro MJ, Fort DJ, Ferrari RA. Cardiotonic activity of milrinone, a new and potent cardiac bipyridine, on the normal and failing heart of experimental animals. J Cardiovasc Pharmacol 1983;5:792-803.
156. Alousi AA, Stankus GP, Stuart JC, Walton LH. Characterization of the cardiotonic effects of milrinone, a new and potent cardiac bipyridine, on isolated tissues from several animal species. J Cardiovasc Pharmacol 1983;5:804-11.
157. Artman M, Kithas PA, Wike JS, Crump DB, Strada SJ. Inotropic responses to cyclic nucleotide phosphodiesterase inhibitors in immature and adult rabbit myocardium. J Cardiovasc Pharmacol 1989;13:146-54.
158. Muller B, Lugnier C, Stoclet JC. Involvement of rolipram-sensitive cyclic AMP phosphodiesterase in the regulation of cardiac contraction. J Cardiovasc Pharmacol 1990;16:796-803.
159. Osadchii O, Norton G, Woodiwiss A. Inotropic responses to phosphodiesterase inhibitors in cardiac hypertrophy in rats. Eur J Pharmacol 2005;514:201-208.
160. Osadchii O, Woodiwiss A, Norton G. Contractile responses to selective phosphodiesterase inhibitors following chronic β-adrenoreceptor activation. Pflugers Arch 2006;452:155-63.
161. Perreault CL, Shannon RP, Shen YT, Vatner SF, Morgan JP. Excitation-contraction coupling in isolated myocardium from dogs with compensated left ventricular hypertrophy. Am J Physiol 1994;266:H2436-42.
162. Rapundalo ST, Solaro RJ, Kranias EG. Inotropic responses to isoproterenol and phosphodiesterase inhibitors in intact gunia-pig hearts: comparison of cyclic AMP levels and phosphorylation of sarcoplasmic reticulum and myofibrillar proteins. Circ Res 1989;64:104-11.
163. Katano Y, Endoh M. Effects of a cardiotonic quinolinone derivative Y-20487 on the isoproterenol-induced positive inotropic action and cyclic AMP accumulation in rat ventricular myocardium: comparison with rolipram, Ro 20-1724, milrinone, and isobutylmethylxanthine. J Cardiovasc Pharmacol 1992;20:715-22.
164. Wynne DG, Poole-Wilson PA, Harding SE. Incomplete reversal of β-adrenoceptor desensitization in human and guinea-pig cardiomyocytes by cyclic nucleotide phosphodiesterase inhibitors. Br J Pharmacol 1993;109:1071-8.
165. Bartel S, Stein B, Eschenhagen T, Mende U, Neumann J, Schmitz W, et al. Protein phosphorylation in isolated trabeculae from nonfailing and failing human hearts. Mol Cell Biochem 1996;157:171-9.
166. Bohm M, Diet F, Feiler G, Kemkes B, Kreuzer E, Weinhold C, et al. Subsensitivity of the failing human heart to isoprenaline and milrinone is related to β-adrenoceptor downregulation. J Cardiovasc Pharmacol 1988;12:726-32.
167. Brown L, Lorenz B, Erdmann E. Reduced positive inotropic effects in diseased human ventricular myocardium. Cardiovasc Res 1986;20:516-20.
168. Feldman MD, Copelas L, Gwathmey JK, Phillips P, Warren SE, Schoen FJ, et al. Deficient production of cyclic AMP: pharmacologic evidence of an important cause of contractile dysfunction in patients with end-stage heart failure. Circulation 1987;75:331-9.
169. Gilbert EM, Hershberger RE, Wiechmann RJ, Movsesian MA, Bristow MR. Pharmacologic and hemodynamic effects of combined β-agonist stimulation and phosphodiesterase inhibition in the failing human heart. Chest 1995;108:1524-32.
170. Wilmshurst PT, Walker JM, Fry CH, Mounsey JP, Twort CH, Williams BT, et al. Inotropic and vasodilator effects of amrinone on isolated human tissue. Cardiovasc Res 1984;18:302-9.
171. Alousi AA, Farah AE, Lesher GY, Opalka CJ. Cardiotonic activity of amrinone-Win 40680 [5-Amino-3,4′-bipyridin-6 (1H)-one]. Circ Res 1979;45:666-77.
172. Bristol JA, Sircar I, Moos WH, Evans DB, Weishaar RE. Cardiotonic agents. 1. 4,5-Dihydro-6-[4-(1H-imidazol-1-y1)phenyl]-3(2H)-pyridazinones: novel positive inotropic agents for the treatment of congestive heart failure. J Med Chem 1984;27:1101-3.
173. Millard RW, Dube G, Grupp G, Grupp I, Alousi A, Schwartz A. Direct vasodilator and positive inotropic actions of amrinone. J Mol Cell Cardiol 1980;12:647-52.
174. Rapundalo ST, Grupp I, Grupp G, Abdul Matlib M, Solaro RJ, Schwartz A. Myocardial actions of milrinone: characterization of its mechanism of action. Circulation 1986;73:III-134-44.
175. Sato N, Asai K, Okumura S, Takagi G, Shannon RP, Fujita-Yamaguchi Y, et al. Mechanisms of desensitization to a PDE inhibitor (milrinone) in conscious dogs with heart failure. Am J Physiol 1999;276:H1699-705.
176. McMartin L, Summers RJ. Functional analysis of desensitization of the beta-adrenoceptor signaling pathway in rat cardiac tissues following chronic isoprenaline infusion. Br J Pharmacol 1999;127:1012-20.
177. Nabauer M, Bohm M, Brown L, Diet F, Eichhorn M, Kemkes B, et al. Positive inotropic effects in isolated ventricular myocardium from non-failing and terminally failing human hearts. Eur J Clin Invest 1988;18:600-6.
178. Endoh M, Yamashita S, Taira N. Positive inotropic effect of amrinone in relation to cyclic nucleotide metabolism in the canine ventricular muscle. J Pharmacol Exp Ther 1982;221:775-83.
179. Korth M. Effects of several phosphodiesterase inhibitors on guinea-pig myocardium. Naunyn-Schmiedeberg's Arch Pharmacol 1978;302:77-86.
180. 2-adrenergic receptor-mediated signaling. Circ Res 2006;99:1084-91.
181. Herzer WA, Thomas NJ, Carcillo JA, Tofovic SP, Jackson EK. Effects of type IV phosphodiesterase inhibition on cardiac function in the presence and absence of catecholamines. J Cardiovasc Pharmacol 1998;32:769-76.
182. Katano Y, Endoh M. Differential effects of Ro 20-1724 and isobutylmethylxanthine on the basal force of contraction and β-adrenoceptor-mediated response in the rat ventricular myocardium. Biochem Biophys Res Commun 1990;167:123-9.
183. Sharma RV, Bhalla RC. Cyclic nucleotide phosphodiesterase in heart and aorta of spontaneously hypertensive rats. Biochim Biophys Acta 1978;526:479-88.
184. Hodgins DS, Frohlich ED. Cardiac adenylate cyclase, cyclic nucleotide phosphodiesterase and lactate dehydrogenase in normotensive and spontaneously hypertensive rats. Biochem Pharmacol 1978;27:1179-85.
185. Klenerova V, Albrecht I, Hynie S. The activity of adenylate cyclase and phosphodiesterase in hearts and aortas of spontaneous hypertensive rats. Pharmacol Res Commun 1975;7:453-62.
186. Ramanathan S, Shibata S, Tasaki TK, Ichord RN. Cyclic AMP metabolism in the cardiac tissue of the spontaneously hypertensive rat. Biochem Pharmacol 1976;25:223-5.
187. Amer MS, Doba N, Reis DJ. Changes in cyclic nucleotide metabolism in aorta and heart of neurogenically hypertensive rats: possible trigger mechanism of hypertension. Proc Natl Acad Sci U S A 1975;72:2135-9.
188. Amer MS, Gomoll AW, Perhach JL, Ferguson HC, McKinney GR. Aberrations of cyclic nucleotide metabolism in the hearts and vessels of hypertensive rats. Proc Natl Acad Sci U S A 1974;71:4930-4.
189. 1-adrenoceptor signal transduction system in pacing-induced failure in dogs with aortic stenosis-induced left ventricular hypertrophy. Mol Cell Biochem 2000;205:67-73.
190. Takahashi K, Osanai T, Nakano T, Wakui M, Okumura K. Enhanced activities and gene expression of phosphodiesterase types 3 and 4 in pressure-induced congestive heart failure. Heart Vessels 2002;16:249-56.
191. Yanaka N, Kurosawa Y, Minami K, Kawai E, Omori K. cGMP-phosphodiesterase activity is up-regulated in response to pressure-overload of rat ventricles. Biosci Biotechnol Biochem 2003;67:973-9.
192. Tse J, Brackett NL, Kuo JF. Alterations in activities of cyclic nucleotide systems and in β-adrenergic receptor-mediated activation of cyclic AMP-dependent kinase during progression and regression of isoproterenol-induced cardiac hypertrophy. Biochim. Biophys Acta 1978;542:399-411.
193. Masunaga R, Nagasaka A, Sawai Y, Hayakawa N, Nakai A, Hotta K, et al. Changes in cyclic nucleotide phosphodiesterase activity and calmodulin concentration in heart muscle of cardiomyopathic hamsters. J Mol Cell Cardiol 2004;37:767-74.
194. 2-adrenoceptor- mediated positive inotropic effects in human end-stage heart failure. Br J Pharmacol 1992;105:463-9.
195. i alpha in right and left ventricles from patients with ischaemic and dilated cardiomyopathy and predominant left ventricular failure. J Mol Cell Cardiol 1994;26:133-49.
196. i alpha-2 in human end-stage heart failure. Circ Res 1992;70:688-96.
197. Jones SM, Hunt NA, Del Monte F, Harding SE. Contraction of cardiac myocytes from noradrenaline-treated rats in response to isoprenaline, forskolin and dibutyryl cAMP. Eur J Pharmacol 1990;191:129-40.
198. Reithmann C, Werdan K. Noradrenaline-induced desensitization in cultured heart cells as a model for the defects of the adenylate cyclase system in severe heart failure. Naunyn-Schmiedeberg's Arch Pharmacol 1989;339:138-44.
199. Harding SE, Jones MS, Vescovo G, Del Monte F, Poole-Wilson PA. Reduced contractile responses to forskolin and a cyclic AMP analogue in myocytes from failing human ventricle. Eur J Pharmacol 1992;223:39-48.
200. Bohm M, Deutsch HJ, Hartmann D, La Rosee K, Stablein A. Improvement of postreceptor events by metoprolol treatment in patients with chronic heart failure. J Am Coll Cardiol 1997;30:992-6.
201. Metra M, Nodari S, D'Aloia A, Muneretto C, Robertson AD, Bristow MR, et al. Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure. J Am Coll Cardiol 2002;40:1248-58.
202. Kotera J, Fujishige K, Akatsuka H, Imai Y, Yanaka N, Omori K. Novel alternative splice variants of cGMP-binding cGMP-specific phosphodiesterase. J Biol Chem 1998;273:26982-90.
203. Senzaki H, Smith CJ, Juang GJ, Isoda T, Mayer SP, Ohler A, et al. Cardiac phosphodiesterase 5 (cGMP-specific) modulates β-adrenergic signaling in vivo and is down-regulated in heart failure. FASEB J 2001;15:1718-26.
204. Takimoto E, Champion HC, Belardi D, Moslehi J, Mongillo M, Mergia E, et al. cGMP catabolism by phosphodiesterase 5A regulates cardiac adrenergic stimulation by NOS3-dependent mechanism. Circ Res 2005;96:100-9.
205. Takimoto E, Champion HC, Li M, Belardi D, Ren S, Rodriguez ER, et al. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nature Med 2005;11:214-22.
206. Corbin J, Rannels S, Neal D, Chang P, Grimes K, Beasley A, Francis S. Sildenafil citrate does not affect cardiac contractility in human or dog heart. Cur Med Res Opin 2003;19:747-52.
207. Loughney K, Hill TR, Florio VA, Uher L, Rosman GJ, Wolda SL, et al. Isolation and characterization of cDNAs encoding PDE5A, a human cGMP-binding, cGMP-specific 3′,5′-cyclic nucleotide phosphodiesterase. Gene 1998;216:139-47.
208. Stacey P, Rulten S, Dapling A, Phillips SC. Molecular cloning and expression of human cGMP-binding phosphodiesterase (PDE5). Biochem Biophys Res Commun 1998;247:249-54.
209. Yanaka N, Kotera J, Ohtsuka A, Akatsuka H, Imai Y, Michibata H, et al. Expression, structure and chromosomal localization of the human cGMP-binding cGMP-specific phosphodiesterase PDE5A gene. Eur J Biochem 1998;255:391-9.
210. Halcox JPJ, Nour KRA, Zalos G, Mincemoyer RA, Waclawiw M, Rivera CE, et al. The effect of sildenafil on human vascular function, platelet activation, and myocardial ischemia. J Am Coll Cardiol 2002;40:1232-40.
211. Herrmann HC, Chang G, Klugherz BD, Mahoney PD. Hemodynamic effects of sildenafil in men with severe coronary artery disease. N Engl J Med 2000;342:1622-6.
212. Tawakol A, Aziz K, Migrino R, Watkowska J, Zusman R, Alpert NM, et al. Effects of sildenafil on myocardial blood flow in humans with ischemic heart disease. Coron Artery Dis 2005;16:443-9.
213. Guazzi M, Tumminello G, Di Marco F, Fiorentini C, Guazzi MD. The effects of phosphodiesterase-5 inhibition with sildenafil on pulmonary hemodynamics and diffusion capacity, exercise ventilatory efficiency, and oxygen uptake kinetics in chronic heart failure. J Am Coll Cardiol 2004;44:2339-48.
214. Lepore JJ, Maroo A, Bigatello LM, Dec GW, Zapol WM, Bloch KD, et al. Hemodynamic effects of sildenafil in patients with congestive heart failure and pulmonary hypertension. Chest 2005;127:1647-53.
215. Michelakis ED, Tymchak W, Noga M, Webster L, Wu X-C, Lien D, et al. Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Circulation 2003;108:2066-9.
216. Hirata K, Adji A, Vlachopoulos C, O'Rourke MF. Effect of sildenafil on cardiac performance in patients with heart failure. Am J Cardiol 2005;96:1436-40.
217. Stief CG, Uckert S, Becker AJ, Harringer W, Truss MC, Forssmann WG, et al. Effects of sildenafil on cAMP and cGMP levels in isolated human cavernous and cardiac tissue. Urology 2000;55:146-50.
218. Sugiyama A, Takeuchi N, Saegusa Y, Sugita M, Hashimoto K. Molecular mechanisms of cardiostimulatory effects of sildenafil. Jpn J Pharmacol 2002;88:362-4.
219. Cremers B, Scheler M, Maack C, Wendler O, Schafers HJ, Sudkamp M, et al. Effects of sildenafil (Viagra) on human myocardial contractility, in vitro arrhythmias, and tension of internal mammaria arteries and saphenous veins. J Cardiovasc Pharmacol 2003;41:734-43.
220. Borlaug BA, Melenovsky V, Marhin T, Fitzgerald P, Kass DA. Sildenafil inhibits β- adrenergic-stimulated cardiac contractility in humans. Circulation 2005;112:2642-9.
221. Chiang CE, Luk HN, Wang TM, Ding PY. Effects of sildenafil on cardiac repolarization. Cardiovasc Res 2002;55:290-9.
222. Inoue H, Yano K, Noto T, Takagi M, Ikeo T, Kikkawa K. T-1032, a novel phosphodiesterase type 5 inhibitor, increases the survival of cardiomyopathic hamsters. Eur J Pharmacol 2002;443:179-84.
223. Fisher PW, Salloum F, Das A, Hyder H, Kukreja RS. Phosphodiesterase-5 inhibition with sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity. Circulation 2005;111:1601-10.
224. Argel MI, Vittone L, Grassi AO, Chiappe LE, Chiappe GE, Cingolani HE. Effect of phosphodiesterase inhibitors on heart contractile behaviour, protein kinase activity and cyclic nucleotide levels. J Mol Cell Cardiol 1980;12:939-54.
225. Vittone L, Chiappe LE, Argel MI, Cingolani HE, Chiappe GE. The mechanical and biochemical effects of pentoxifylline on the perfused rat heart. Experientia 1980;36:1088-90.
226. Henry PD, Dobson JG, Sobel BE. Dissociations between changes in myocardial cyclic adenosine monophosphate and contractility. Circ Res 1975;36:392-400.
227. Kelso EJ, McDermott BJ, Silke B. Cardiotonic actions of selective phosphodiesterase inhibitors in rat isolated ventricular cardiomyocytes. Br J Pharmacol 1993;110:1387-94.
228. Zaccolo M, Pozzan T. Discrete microdomains with high concentration of cAMP in stimulated rat neonatal cardiac myocytes. Science 2002;295:1711-5.
229. Dodge-Kafka KL, Soughayer J, Pare GC, Carlisle Michel JJ, Langeberg LK, Kapiloff MS, et al. The protein kinase A anchoring protein mAKAP coordinates two integrated cAMP effector pathways. Nature 2005;437:574-8.
230. Verde I, Pahlke G, Salanova M, Zhang G, Wang S, Coletti D, et al. Myomegalin is a novel protein of the Golgi/centrosome that interacts with a cyclic nucleotide phosphodiesterase. J Biol Chem 2001;276:11189-98.
231. Dodge KL, Khouangsathiene S, Kapiloff MS, Monton R, Hill EV, Houslay MD, et al. mAKAP assembles a protein kinase A/PDE4 phosphodiesterase cAMP signaling module. EMBO J 2001;20:1921-30.
232. Kapiloff MS, Schillace RV, Westphal AM, Scott JD. mAKAP: an A-kinase anchoring protein targeted to the nuclear membrane of differentiated myocytes. J Cell Sci 1999;112:2725-36.
233. Yang J, Drazba JA, Ferguson DG, Bond M. A-kinase anchoring protein 100 (AKAP100) is localized in multiple subcellular compartments in the adult rat heart. J Cell Biol 1998;142:511-22.
234. i. Proc Natl Acad Sci U S A 2003;100:940-5.
235. 2- adrenergic receptors by β-arrestins. Science 2002;298:834-6.
236. Kapiloff MS, Jackson N, Airhart N. mAKAP and the ryanodine receptor are part of a multicomponent signaling complex on the cardiomyocyte nuclear envelope. J Cell Sci 2001;114:3167-76.
237. Rubin CS. A kinase anchor proteins and the intracellular targeting of signals carried by cyclic AMP. Biochim Biophys Acta 1994;1224:467-79.
238. Lefkowitz RJ, Shenoy SK. Transduction of receptor signals by beta-arrestins. Science 2005;308:512-7.
239. 2-adrenergic receptor to different G-proteins by protein kinase A. Nature 1997;390:88-91.
240. 2+ dynamics, contractility or phospholamban phosphorylation. J Biol Chem 1994;269:19151-6.
241. Houslay MD, Baillie GS. Phosphodiesterase-4 gates the ability of protein kinase A to phosphorylate G-protein receptor kinase-2 and influence its translocation. Biochem Soc Trans 2006;34:474-5.
242. Picq M, Dubois M, Grynberg A, Lagarde M, Prigent AF. Specific effects of n-3 fatty acids and 8-bromo-cGMP on the cyclic nucleotide phosphodiesterase activity in neonatal rat cardiac myocytes. J Mol Cell Cardiol 1996;28:2151-61.
243. Gando S, Hattori Y, Akaishi Y, Nishihira J, Kanno M. Impaired contractile response to beta-adrenoceptor stimulation in diabetic rat hearts: alterations in beta-adrenoceptors-G- protein-adenylate cyclase system and phospholamban phosphorylation. J Pharmacol Exp Ther 1997;282:475-84.
244. +-induced contracture of normal and subacutely failed cat ventricular muscle. Circulation 1986;73:III-36-45.
245. Bohm M, Morano I, Pieske B, et al. Contribution of cAMP-phosphodiesterase inhibition and sensitization of the contractile proteins for calcium to the inotropic effect of pimobendan in the failing human myocardium. Circ Res 1991;68:689-701.
246. Schumacher C, Becker H, Conrads R, Schotten U, Pott S, Kellinghaus M, et al. Hypertrophic cardiomyopathy: a desensitized cardiac β-adrenergic system in the presence of normal plasma catecholamine concentrations. Naunyn-Schmiedeberg's Arch Pharmacol 1995;351:398-407.
247. Gutstein DE, Flemmal K, Bruce E, Travers KE, Gwatmey JK, Ramsil BJ, et al. Decreased inotropic but relatively preserved relaxation response to cyclic adenosine monophosphate-dependent agents in myopathic human myocardium. J Card Fail 1996;2:285-92.